Free tool
FAERS Monitor: Advair Diskus 500/50
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021077 or its brand name (Advair Diskus 500/50, Fluticasone Propionate, Salmeterol Xinafoate). Reports on generic versions are filed under their own applications.
Reports
37,187
Serious
15,488
42% of reports
Hospitalization
8,624
Death reported
1,918
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea5,839
- drug ineffective4,379
- product quality issue2,508
- cough2,235
- product dose omission issue2,116
- pneumonia2,059
- drug dose omission1,996
- asthma1,915
- malaise1,509
- wrong technique in device usage process1,483
- device use error1,445
- chronic obstructive pulmonary disease1,308
- underdose1,241
- off label use1,193
- dysphonia1,182
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 163 |
| 2005 | 79 |
| 2006 | 13 |
| 2007 | 15 |
| 2008 | 16 |
| 2009 | 34 |
| 2010 | 328 |
| 2011 | 624 |
| 2012 | 1,675 |
| 2013 | 4,671 |
| 2014 | 3,787 |
| 2015 | 5,405 |
| 2016 | 3,618 |
| 2017 | 3,249 |
| 2018 | 3,280 |
| 2019 | 2,604 |
| 2020 | 1,753 |
| 2021 | 1,204 |
| 2022 | 1,130 |
| 2023 | 936 |
| 2024 | 1,089 |
| 2025 | 586 |
| 2026 | 925 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,972 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device use errorSignal | 1,445 | 24.5 | 23.3 | 31,243 |
| wrong technique in device usage processSignal | 1,483 | 18.5 | 17.6 | 23,826 |
| chronic obstructive pulmonary diseaseSignal | 1,308 | 14.5 | 13.8 | 16,076 |
| dysphoniaSignal | 1,182 | 11.6 | 11.0 | 11,290 |
| product quality issueSignal | 2,508 | 10.6 | 10.2 | 21,586 |
| underdoseSignal | 1,241 | 9.8 | 9.2 | 9,622 |
| asthmaSignal | 1,915 | 9.7 | 9.3 | 14,820 |
| drug dose omissionSignal | 1,996 | 6.9 | 6.6 | 10,022 |
| dyspnoeaSignal | 5,839 | 5.9 | 5.7 | 24,071 |
| coughSignal | 2,235 | 4.5 | 4.4 | 6,190 |
| product dose omission issueSignal | 2,116 | 4.1 | 3.9 | 4,975 |
| pneumoniaSignal | 2,059 | 3.6 | 3.5 | 3,925 |
| malaise | 1,509 | 1.9 | 1.9 | 709 |
| drug ineffective | 4,379 | 1.9 | 1.8 | 1,924 |
| off label use | 1,193 | 0.8 | 0.7 | 85 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.